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● ● ● CLINICAL OBSERVATIONS
Comment on Breunis et al, page 1029
The yin and yang of Fc receptors in ITP
----------------------------------------------------------------------------------------------------------------
Steven E. McKenzie CARDEZA FOUNDATION FOR HEMATOLOGICAL RESEARCH, THOMAS JEFFERSON
UNIVERSITY
In this issue ofBlood, Breunis and colleagues examine the role of genetic variation
in the human Fc receptors for IgG in the susceptibility to idiopathic thrombocyto-
penic purpura (ITP).
The Fc receptors contribute to the suscep-tibility to autoimmune diseases such as
ITP in several ways: (1) theymodulate den-
dritic cell antigen processing and presentation,
(2) theymodulate antibody production by
B cells, and (3) they participate in effector cell
functions, such as phagocytosis, antibody-
dependent cellular cytotoxicity, andmediator
release. The key finding in recent years has
been the appreciation that the activating Fc
receptors, encoded by FCGR2A, -2C, -3A,
and -3B, compete with the inhibitory Fc re-
ceptor, encoded by FCGR2B, to determine
cellular responses to immune complexes and
antibody-coated cells.
The work by this team, led byDrTaco
Kuijpers, is noteworthy for several reasons.
First, the authors have achieved a technical
tour-de-force, developing
multiplex ligation-
dependent polymerase
amplification assays (ML-
PAs) to simultaneously
identify both single nucleo-
tide polymorphisms
(SNPs) and copy number
variations (CNVs) in the 5
gene locus containing the
so-called low-affinity Fc
receptors for IgG:
FCGR2A, -2B, -2C, -3A,
and -3B. These genes are
highly homologous, and
genetic studies of this re-
gion are notoriously diffi-
cult. The authors typed 8
biologically significant
variations at the same time.
Second, they discovered a
newCNV for the
FCGR3A gene. Third,
their assays combined the
ability to identify an im-
portant FCGR2CSNP (ORF, open reading
frame, versus STP, stop codon) with the abil-
ity to detect deletion or duplication of a block
containing the adjacent FCGR2C and
FCGR3B genes. Finally, in a study comparing
the frequency of these FCGR2,3 gene varia-
tions in healthy individuals versus in children
and adults with ITP, analyzed separately and
as a group, they discovered a significant over-
representation of the FCGR2CORF allele in
individuals with ITP. The team convincingly
confirmed the work by Ernst, Herberman, and
colleagues1 that the FCGR2C genotype deter-
mines the phenotype, with respect to protein
expression and function. Since FCGR2C is an
activating receptor inmonocytes/macro-
phages and natural killer (NK) cells, the find-
ings are consistent with the current paradigm
in the field that the balance of activating versus
inhibitory Fc receptors contributes to sus-
ceptibility to autoimmune disease (see figure).
Where does the field go from here? These
8 genetic variations are not in linkage disequi-
librium, but individuals will be endowed in
this region of chromosome 1q23 with a haplo-
type of FCGR2,3 SNPs andCNV that can
influence the susceptibility to ITP and other
auto- or allo-immune disorders. In the figure,
the hypothesized set of alleles conferring
greater susceptibility is contrasted to the set
conferring lesser susceptibility. Further tech-
nical advances and larger numbers of patients
and controls, especially those of diverse ethnic
groups, will be needed to test the potential
clinical value of assaying genetic differences in
susceptibility. Equally exciting, however, is
the prospect that these genetic variations con-
tribute to differences in the response to thera-
peutics for ITP.Modulation of Fc receptor
activating and inhibitory functions aremain-
stays of ITP treatment.2-4Wemay even go so
far as to link responses to a broader set of anti-
body therapeutics for human disease to the
haplotype of FCGR2,3 genetic variations.
Conflict-of-interest disclosure: The author
declares no competing financial interests. ■
The SNP and CNV alleles in the human FCGR2,3 gene locus at chromo-
some 1q23 that contribute to susceptibility to autoimmune disease are
shown schematically, including the genetic variation in FCGR2C in the
study on ITP by Breunis et al. (The alleles are defined in that article.) The
balance of activation and inhibition contributes to greater or lesser sus-
ceptibility to autoimmune disease.
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Comment on Shida et al, page 1295
Shear elegance: regulation of thrombus
growth by shear stress
----------------------------------------------------------------------------------------------------------------
William E. Hobbs II and Jose´ A. Lo´pez PUGET SOUND BLOOD CENTER
Anew study by Shida et al provides an elegant explanation for how vessel wall inju-
ries are repaired without occluding the vessel.
Thehemostatic repair of damaged endovascu-lature resembles an intricate symphonyor-
chestratedbyplatelets and a variety of plasma
proteins, all tightly regulated toprevent lumen
occlusion and thromboembolism.Onekey
player in this symphony, vonWillebrand factor
(VWF), functions to bridge exposed collagen on
damaged subendothelial surfaces to receptors on
circulatingplatelets and to bridgeplatelets to
each other as the thrombus grows.1 Its ability to
performboth tasks relates to the size of itsmul-
timers and exposure to shear stress.
VWF is synthesized in only 2 cell types, en-
dothelial cells andmegakaryocytes, and is re-
leased constitutively by endothelial cells or from
storage granules of endothelial cells or platelets
in response to secretagogues.TheVWFnewly
released fromgranules is enormous (hence the
designationultra-largeVWForULVWF) and
hyperadhesive.2ADAMTS13 rapidly converts
ULVWFto smaller and less adhesive species
throughproteolytic cleavage at the peptide bond
Y1605-M1606within theA2domain. Proteoly-
sis is enhancedby shear stress3 andbyplatelet
binding.4 Shear stress is also one of the variables
that enhances the binding of plasmaVWFto
platelets.5 In this issue ofBlood, Shida and col-
leagues provide a fascinating explanation for how
shear stress can facilitate platelet thrombus for-
mationwhile simultaneously limiting thrombus
growth. In a simple and elegant experiment, the
investigators examined the contribution of
ADAMTS13 activity to the growthof platelet
thrombi at different shear stresses.Theyper-
fusedbloodover a collagen-coated surface in a
perfusion chamber andused 2 very valuable
monoclonal antibodies to probeADAMTS13
functions: one that blockedADAMTS13 activ-
ity andone that boundonly afterADAMTS13
cleavedVWF(N10).As expected,ADAMTS13
blockade increased thrombus growth rate and
volume concurrentwithdecreasedN10 antibody
binding.WhenADAMTS13wasunopposed,
N10binding increased, indicating increased
VWFcleavage in the smaller thrombi that re-
sulted, a phenomenon that becamemorepro-
nouncedwith increased shear stress.N10 stain-
ing also increasedwith increaseddistance from
thebase of the thrombus, being greatest at the
surface.Extrapolated to a high-shearmural
thrombus in vivo, these results suggest that as
shear stress increases byprogressive luminal
narrowing, so does cleavage ofVWFby
ADAMTS13.Thus, not only does
ADAMTS13 controlVWFreactivity by reduc-
ing the size and reactivity of its ultra-large forms,
italsoactsontheformofVWFnormally foundin
plasmaas itparticipates inthebuildupof thrombi.
These findings suggest a mechanism that
allows repair of vessel wall defects without the
repair process completely occluding the vessel.
They also provide further insight into the
pathophysiology of themost extrememanifes-
tation of ADAMTS13 deficiency: thrombotic
thrombocytopenic purpura (TTP). In TTP,
ADAMTS13 deficiencymay have 2 important
but distinct roles: first, it allowsULVWF to
linger on the vessel wall and bind the first layer
of platelets; and second, it is unable to prevent
platelets that attach to the thrombus subse-
quently from completely occluding the vessel.
This elegant study also demonstrates that
experiments need not be particularly compli-
cated in nature or technologically difficult to
providemechanistic insights; they just have to
be carefully considered.
Conflict-of-interest disclosure: The authors
declare no competing financial interests. ■
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Sexuality in long-term survivors
----------------------------------------------------------------------------------------------------------------
Gerard Socie´ HOSPITAL SAINT LOUIS
In this issue ofBlood, Syrjala and coworkers highlight that sexual recovery in long-
term survivors after allogeneic stem-cell transplantationmay well be themost fre-
quent late effect ever reported.
The number of long-term survivors of he-matopoietic cell transplantation (HCT) is
increasing rapidly; worldwide, more than
45 000 patients receiveHCT each year. Pa-
tients with leukemias who survive without
recurrent malignancy for 2 years after alloge-
neic HCT currently have an 89%probability
of surviving for 5 ormore years. Research on
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